Investigational Alzheimer's therapy update describing interim clinical findings and the company's plans for a larger, controlled follow‑up study.
Key Takeaways
- No drug-related serious adverse events were observed among seven evaluable participants
- Eighty percent of biomarker-selected patients showed over 30% TSPO-PET reductions
- One TSPO-PET responder experienced an eight-point MMSE improvement from baseline